Sparrow Pharmaceuticals Expands Cohorts in Phase 2b Diabetes Trial
Sparrow Pharmaceuticals announced expansion cohorts in its Phase 2b CAPTAIN-T2D trial to evaluate clofutriben across a range of cortisol levels in difficult-to-control type 2 diabetes.